Skip to content
ContentLora

    Tip: press / anywhere to search.

    ● Developing story

    Meningitis outbreaks and vaccine news tracker, 2025-2026

    In 2026 England had an unusually fast MenB outbreak in Kent, with fifteen cases in 48 hours and two deaths, then launched a one-off MenB vaccine programme for new students.[1][2][3] US meningococcal cases reached 463 in 2025, driven by serogroup Y. US vaccine recommendations were cut back in January 2026, and a court restored the earlier schedule in March.[4][5][6]

    Editor reviewedStrict sourcingUpdated DevelopingHealth and medicine, Tech policy

    What we know

    • The March 2026 Kent MenB outbreak caused fifteen cases within 48 hours and two deaths[1]
    • A separate MenB cluster of three cases in Weymouth, Dorset, involved a different strain[11]
    • The UK's one-off MenB programme offers first doses until 31 December 2026 and second doses until 31 March 2027[14]
    • The US reported 463 meningococcal cases in 2025 (preliminary), driven largely by serogroup Y[4]
    • Penicillin- and ciprofloxacin-resistant serogroup Y strains have been detected in the US since 2019[15]
    • The January 2026 US schedule change is stayed, and CDC again lists routine MenACWY at ages 11-12[6]
    • African meningitis belt countries reported 21,526 suspected cases and 971 deaths in 2025[18]

    What we don't know yet

    • What UKHSA's genomic and immunity studies find about why the Kent outbreak spread so fast
    • Whether the JCVI will recommend routine MenB vaccination for adolescents or students after its review
    • How many eligible young people complete both MenB doses before the programme closes
    • How the First Circuit will rule on the stay of the US vaccine schedule changes
    • Whether the US serogroup Y rise continues through the 2027 winter peak
    Story status

    Story status

    State
    developing
    Started
    2023-10-20
    Timeline entries
    11
    Last entry

    Timeline data (JSON)

    This tracker follows meningococcal outbreaks and meningitis vaccine decisions, mainly in the UK and US, with dated entries. Meningococcal disease is uncommon but serious: even with antibiotics, 10 to 15 in 100 patients die.[7] This page is not medical advice; ask a clinician whether you or your child should be vaccinated, and seek emergency care for suspected meningitis.

    England’s 2026 MenB outbreaks

    England normally diagnoses about 300 to 400 meningococcal cases a year.[8] In March 2026 a MenB outbreak in Kent produced fifteen cases within 48 hours. UKHSA says most outbreaks it manages involve 2 to 4 cases over a longer period.[1] Two people died.[2] Antibiotics and vaccine were offered to close contacts, students living on the Canterbury campus and people who had visited a Canterbury nightclub between 5 and 15 March.[9] UKHSA said the risk to the wider public stayed low, because MenB needs close, prolonged contact to spread.[10] In April, three young people in Weymouth, Dorset, had MenB caused by a different strain. All were recovering.[11]

    The UK’s one-off MenB programme

    In June 2026 the UK announced a time-limited MenB programme while the JCVI, its vaccine advisory committee, reviews the evidence.[3] Before the outbreaks, the JCVI did not recommend routine MenB vaccination for adolescents.[12] The programme covers 17- and 18-year-olds born between September 2007 and August 2008, and under-25s starting university or residential further education for the first time in autumn 2026.[3] UKHSA says first-year students face about 7 times the risk of peers who do not go to university.[13] First doses are available until 31 December 2026 and second doses until 31 March 2027.[14]

    United States: rising cases and shifting policy

    US cases have risen sharply since 2021. The CDC counted 463 in 2025 (preliminary), the second-highest total since 2013, with serogroup Y driving much of the increase.[4] The CDC has detected serogroup Y strains resistant to penicillin and ciprofloxacin since 2019.[15] On 5 January 2026 HHS moved MenACWY and MenB to high-risk groups and put meningococcal vaccination for other children under shared clinical decision-making.[5] A federal court stay on 16 March 2026 blocked that change. CDC guidance reviewed on 30 March again lists routine MenACWY at ages 11-12.[6][16] The government has appealed.[17] The arguments are set out in the policy debate page, and the wider fight over US vaccine advice is covered in the US mRNA vaccine policy debate.

    The global picture

    The African meningitis belt carries the highest burden. In 2025 its surveillance network reported 21,526 suspected cases and 971 deaths.[18] A five-serogroup conjugate vaccine (Men5CV) was prequalified by WHO in 2023, and Niger ran the first Gavi-supported preventive campaign in 2025.[19] The CDC notes that Hajj and Umrah pilgrimages have been linked to outbreaks, including 6 US cases in 2024.[20]

    Timeline

    11 confirmed

    1. confirmed

      UK MenB catch-up open; first doses close 31 December 2026[14]

      The US appeal over the vaccine schedule stay is still pending.

    2. confirmed

      UK announces a one-off MenB vaccine programme for school leavers and new students[3][13]

    3. confirmed

      Three MenB cases in Weymouth, Dorset, from a different strain[11]

    4. confirmed

      UKHSA details a fast-moving MenB outbreak in Kent; two people died[2][1][9]

    5. confirmed

      Court stay blocks the January schedule change; earlier recommendations return[24][6]

    6. confirmed

      HHS moves MenACWY and MenB off the universal US childhood schedule[5][23]

    7. confirmed

      US records 463 meningococcal cases in 2025, second-most since 2013[4]

      Preliminary CDC data; serogroup Y drives much of the rise since 2021.

    8. confirmed

      Meningitis belt reports 21,526 suspected cases and 971 deaths for 2025[18]

    9. confirmed

      ACIP recommends Penmenvy when MenACWY and MenB are due together[22]

    10. confirmed

      FDA licenses a second pentavalent vaccine, GSK's Penmenvy[22]

    11. confirmed

      FDA approves Penbraya, the first pentavalent MenABCWY vaccine[21]

    Next in the crash course

    More in Health & medicine

    Developing in Health

    Questions readers ask

    What happened in the Kent meningitis outbreak?

    In March 2026 a MenB outbreak centred on Canterbury produced fifteen cases within 48 hours, far faster than the 2 to 4 cases typical of UK outbreaks, and two people died. UKHSA offered antibiotics and MenB vaccine to close contacts, students and visitors to a local nightclub.[1][2][9]

    Who can get the free MenB vaccine in the UK?

    17- and 18-year-olds born between 1 September 2007 and 31 August 2008, and under-25s starting university or residential further education for the first time in autumn 2026. First doses are available until 31 December 2026.[3][14]

    Are meningococcal cases rising in the US?

    Yes. The CDC says cases have risen sharply since 2021 and reached 463 in 2025 (preliminary), the second-highest count since 2013, with serogroup Y driving much of the rise.[4]

    Is MenACWY still recommended for US teenagers?

    CDC guidance reviewed in March 2026 recommends MenACWY for all 11- to 12-year-olds with a booster at 16. A January 2026 change that moved it to high-risk groups was blocked by a court stay in March.[16][6]

    Sources

    · 24 claims from 10 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      UKHSA called the Kent outbreak unusually fast, with fifteen cases emerging within 48 hours, whereas most outbreaks it manages involve 2 to 4 cases over a longer period. confirmedas of 2026-03-18

    2. [2]

      A meningococcal disease outbreak in Kent, England, in March 2026 was linked to a MenB strain, and two people died. confirmedas of 2026-03-18

    3. [3]

      The UK introduced a one-off, time-limited MenB vaccine programme in response to the 2026 outbreaks while JCVI reviews the evidence, offering two doses to 17- and 18-year-olds born 1 September 2007-31 August 2008 and to under-25s starting university or residential further education for the first time in autumn 2026. confirmedas of 2026-06-12

    4. [4]

      The US reported 463 confirmed and probable meningococcal cases in 2025 (preliminary), the second-highest count since 2013; cases have risen sharply since 2021, driven largely by serogroup Y, and generally peak each year in January to March. confirmedas of 2026-09-29

    5. [5]

      On 5 January 2026 HHS cut the number of diseases covered by universally recommended childhood vaccines from 17 to 11, moving MenACWY and MenB to high-risk groups and placing meningococcal vaccination under shared clinical decision-making for others. confirmedas of 2026-01-09

    6. [6]

      The 16 March 2026 court stay blocked the January 2026 schedule memo and returned the childhood schedule to its earlier form; CDC's meningococcal guidance, reviewed on 30 March 2026, again lists routine MenACWY at ages 11-12. confirmedas of 2026-10-11

    7. [7]

      Even with antibiotic treatment, 10 to 15 in 100 people with meningococcal disease die, and one in five survivors has long-term disabilities. confirmedas of 2026-10-11

    8. [8]

      Around 300 to 400 cases of meningococcal disease are diagnosed in England every year. confirmedas of 2026-03-18

    9. [9]

      In the Kent outbreak UKHSA offered preventive antibiotics and MenB vaccine to close contacts, University of Kent students resident on the Canterbury campus and people who visited a Canterbury nightclub between 5 and 15 March. confirmedas of 2026-03-18

    10. [10]

      UKHSA said the risk to the wider public from the Kent outbreak remained low because MenB is less contagious than measles or COVID-19 and needs close, prolonged contact to spread. confirmedas of 2026-03-18

    11. [11]

      In April 2026 three young people in Weymouth, Dorset, had MenB caused by a different strain from the Kent outbreak; all were treated and recovering, and UKHSA offered antibiotics and vaccine to secondary-school-age young people in the area. confirmedas of 2026-04-17

    12. [12]

      As of March 2026 the UK's Joint Committee on Vaccination and Immunisation did not recommend a routine MenB booster for adolescents and young adults, and UKHSA asked it to review the Kent outbreak. confirmedas of 2026-03-18

    13. [13]

      UKHSA says first-year university students have a meningococcal disease risk about 7 times higher than young people of similar age who do not go to university, and that after infancy cases peak at ages 18-19. confirmedas of 2026-06-12

    14. [14]

      Under the UK one-off programme, first MenB doses are available until 31 December 2026 and second doses until 31 March 2027. confirmedas of 2026-10-11

    15. [15]

      Since 2019 the CDC has detected penicillin- and ciprofloxacin-resistant serogroup Y meningococcal isolates in the United States. confirmedas of 2026-09-29

    16. [16]

      CDC guidance (reviewed March 2026) recommends a MenACWY vaccine for all 11- to 12-year-olds and a booster at 16 because protection wanes. confirmedas of 2026-10-11

    17. [17]

      The federal government appealed the March 2026 ruling to the First Circuit (No. 26-1503), and district court proceedings were paused pending the appeal. confirmedas of 2026-09-30

    18. [18]

      In 2025, 24 of the 26 countries in the African meningitis belt's enhanced surveillance network reported 21,526 suspected meningitis cases and 971 deaths to WHO, a case fatality rate of 4.5%. confirmedas of 2026-10-11

    19. [19]

      In 2023 WHO prequalified the first pentavalent meningococcal conjugate vaccine against serogroups A, C, W, Y and X (Men5CV) for the African meningitis belt, and Niger ran the first Gavi-supported preventive Men5CV campaign in 2025. confirmedas of 2026-10-11

    20. [20]

      The CDC Yellow Book says meningococcal vaccination is not recommended for travel outside the African meningitis belt unless there is an ongoing outbreak, and that the Hajj and Umrah pilgrimages have been linked to outbreaks, including 6 cases among Umrah participants and contacts in the US in 2024. confirmedas of 2026-10-11

    21. [21]

      The FDA approved Pfizer's pentavalent Penbraya (MenACWY-TT/MenB-FHbp) on 20 October 2023 for people aged 10-25, and ACIP recommended it on 25 October 2023 for use when both MenACWY and MenB are indicated at the same visit. confirmedas of 2024-04-18

    22. [22]

      The FDA licensed GSK's pentavalent Penmenvy (MenACWY-CRM/MenB-4C) on 14 February 2025 for people aged 10-25, and ACIP recommended it on 16 April 2025 for use when both MenACWY and MenB are indicated at the same visit. confirmedas of 2026-01-08

    23. [23]

      Medical groups including the American College of Physicians and the American Academy of Pediatrics opposed the January 2026 schedule change, and the AAP kept its own recommendations unchanged. confirmedas of 2026-01-09

    24. [24]

      On 16 March 2026 a federal district court in Massachusetts, in American Academy of Pediatrics v. Kennedy, stayed the 13 ACIP appointments and all votes of the reconstituted committee since June 2025. confirmedas of 2026-03-17

    Revision history (1)
    1. Page created.

    Created Oct 11, 2026. Last reviewed by an editor on Oct 11, 2026. Next scheduled review: Dec 31, 2026.

    Cite this page

    "Meningitis outbreaks and vaccine news tracker, 2025-2026." ContentLora, updated Oct 11, 2026. https://contentlora.com/events/meningitis-outbreaks-tracker

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    ☰ Contents